OnKure Therapeutics, Inc.

OKUR: 8-K · leadership change

On August 7, 2026, the board of OnKure Therapeutics approved an option repricing that reset the exercise price on roughly 1.7 million underwater stock options to $4.14, the stock's closing price that day. The repriced options had original exercise prices ranging from $13.99 to $24.59 per Share. The repricing covered all outstanding unexercised options granted before January 1, 2025 under the company's 2024 Equity Incentive Plan or 2021 Stock Incentive Plan with exercise prices of $10.00 or higher — approximately 40% of outstanding options under the Plans — held by certain employees and consultants, including all named executive officers. CEO Nicholas Saccomano had 571,423 shares of options repriced, CMO Samuel Agresta 149,984, and CFO Jason Leverone 141,714. Optionees must remain with the company to keep the lower price — 18 months for senior management and one year for others — otherwise they pay a premium equal to the original exercise price. The company says the design preserves retention incentives while avoiding the dilution of new grants or cash compensation costs. For investors, the action is a fresh signal of how far OKUR shares have fallen from the strike levels set in prior grants, and repricings after sharp declines are typically viewed as value transfers to insiders, though the retention locks partially offset that concern.

SEC 8-K•2mo ago

OKUR: 424B5 · prospectus supplement

OnKure Therapeutics filed a prospectus supplement registering up to $100,000,000 of Class A common stock for sale from time to time under its at-the-market program, with Leerink Partners acting as sales agent for a commission of up to 3.0% of gross proceeds. The supplement amends the November 26, 2025 ATM prospectus because OnKure is no longer subject to the General Instruction I.B.6 offering limit on Form S-3; the company disclosed that as of August 4, 2026 it had not yet offered or sold any shares under the prior prospectus. The new capacity is large relative to the company's size: the market value of Class A shares held by non-affiliates was $167.3 million (36,368,892 shares at a $4.60 reference price), so substantial sales under the ATM would be meaningfully dilutive to OKUR holders.

SEC 424B5•2mo ago

OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies

globenewswire.com•6mo ago